Psoriasis – Current Treatment – Detailed, Expanded Analysis Adult Psoriasis – Treatment Algorithms – Claims Data Analysis (US)
Adult psoriasis represents an increasingly lucrative market for biologics to treat the moderate to severe population, for whom conventional systemic and topical treatments alone are not sufficient. Of the targeted therapies, Novartis’s interleukin (IL)-17 inhibitor, Cosentyx; Janssen’s IL-12/23 inhibitor, Stelara; and AbbVie’s TNF-α inhibitor, Humira, dominate the landscape. The only oral, targeted therapy, Amgen’s Otezla, also holds a substantial patient share. However, the patient shares of established targeted agents are increasingly being challenged by the arrival of later-to-market biologics—such as Janssen’s Tremfya, AbbVie's Skyrizi, and Eli Lilly’s Taltz—leading to interesting dynamics in the psoriasis market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
- How have newer biologics such as Skyrizi, Tremfya, and Taltz been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: AbbVie, Amgen, Bausch Health, Eli Lilly, Janssen, Novartis, UCB
Key drugs: Cimzia, Cosentyx, Duobrii, Enbrel, Humira, Otezla, Remicade, Skyrizi, Stelara, Taltz, Tremfya
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketer scan accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Table of contents
- Psoriasis - Current Treatment - Detailed, Expanded Analysis Adult Psoriasis - Treatment Algorithms - Claims Data Analysis (US)
- Treatment-Algorithms-Claims-Data-Analysis-Adult-Psoriasis-US-April-2022
- Treatment Algorithms CDA Psoriasis (Adult) US 2021 Dashboard
Mohit Nasa, M.B.A., is a principal analyst on the Immune and Inflammatory Disorders team at Clarivate. He has authored content on such indications as systemic lupus erythropoiesis, psoriasis, asthma, and rheumatoid arthritis. Previously, he worked as a senior business analyst at Novartis, where he was responsible for end-to-end market assessment and related projects for Novartis’s asthma brand Xolair. Mr. Nasa holds a bachelor’s degree in pharmacy and an M.B.A. in marketing and CRM from Amity Business School in India.